Evidence map›Paper›PMID 42876279›Full record

ReviewChemical Society reviews2026

New approach methodologies in nanomedicine: bridging the gap between

Yasmine Radwan, Laura P Rebolledo, Elizabeth Skelly, Emma Grabarnik, Sankalp Jain, Morgan Halman, Roger Chammas, Alexey V Zakharov, Marina A Dobrovolskaia, Kirill A Afonin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Chemical Society reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yasmine RadwanChemistry and Nanoscale Science Program, Department of Chemistry, University of North Carolina at Charlotte, Charlotte, NC 28223, USA. kafonin@charlotte.edu.ORCID http://orcid.org/0000-0002-8383-9033
Laura P RebolledoChemistry and Nanoscale Science Program, Department of Chemistry, University of North Carolina at Charlotte, Charlotte, NC 28223, USA. kafonin@charlotte.edu.
Elizabeth SkellyChemistry and Nanoscale Science Program, Department of Chemistry, University of North Carolina at Charlotte, Charlotte, NC 28223, USA. kafonin@charlotte.edu.
Emma GrabarnikNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA. marina@mail.nih.gov.
Sankalp JainNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, USA.ORCID http://orcid.org/0000-0002-9370-9611
Morgan HalmanMIMETAS US, Gaithersburg, MD 20878, USA.
Roger ChammasCenter for Translational Research in Oncology (LIM/24), Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo 01246-000, Brazil.ORCID http://orcid.org/0000-0003-0342-8726
Alexey V ZakharovNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, USA.ORCID http://orcid.org/0000-0003-2466-1711
Marina A DobrovolskaiaNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA. marina@mail.nih.gov.ORCID http://orcid.org/0000-0002-4233-9227
Kirill A AfoninChemistry and Nanoscale Science Program, Department of Chemistry, University of North Carolina at Charlotte, Charlotte, NC 28223, USA. kafonin@charlotte.edu.ORCID http://orcid.org/0000-0002-6917-3183

Funding

SMART NANPs: new molecular platform for communication with human immune system and modulation of therapeutic responsesR35GM139587 · NIGMS · UNIVERSITY OF NORTH CAROLINA CHARLOTTE · PI AFONIN, KIRILL A · 2021 to 2025
$1.8M
NIGMS NIH HHS R35 GM139587
6 · The paper itself

Abstract

The rise of nanomedicine has led to the regulatory approval of more than 80 nanoparticle (NP)-based therapeutics over the past two decades. Further advancement in the field requires a deeper understanding of the nano-bio interface of NPs, including their uptake, delivery, efficacy, toxicity, and adverse effects. Despite the heavy reliance on conventional cell cultures for NP screening, these models do not recapitulate the

Identifiers

PMID42876279
PMCPMC13669715

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.